Truist Financial analyst Jailendra Singh maintained a Buy rating on Progyny (PGNY – Research Report) today. The company’s shares closed yesterday at $36.51.
Singh covers the Healthcare sector, focusing on stocks such as R1 RCM, Progyny, and GoodRx Holdings. According to TipRanks, Singh has an average return of -12.7% and a 36.05% success rate on recommended stocks.
Progyny has an analyst consensus of Strong Buy, with a price target consensus of $47.63, implying a 30.46% upside from current levels. In a report released on March 19, Leerink Partners also maintained a Buy rating on the stock with a $48.00 price target.
The company has a one-year high of $44.95 and a one-year low of $29.44. Currently, Progyny has an average volume of 823.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Progyny (PGNY) Company Description:
Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.
Read More on PGNY:
- Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum
- Progyny, Inc. to Present at Barclays 26th Annual Global Healthcare Conference
- Progyny announces $100M share repurchase program
- Progyny, Inc. Announces Share Repurchase Program
- Progyny price target raised to $50 from $45 at BTIG
